key: cord-0020960-s5v8qwni
authors: Mansour, Samer; Haddad, Kevin
title: Pushing TAVR Beyond the Boundaries of a Surgery-Capable Center: Malpractice or a Rescue Plan?
date: 2021-07-08
journal: Cardiovasc Revasc Med
DOI: 10.1016/j.carrev.2021.07.001
sha: 596a7ea435ac8e99b27651d386b2ccb604f936f2
doc_id: 20960
cord_uid: s5v8qwni

nan

Pushing TAVR Beyond the Boundaries of a Surgery-Capable Center: Malpractice or a Rescue Plan?

A study by Joseph et al. in this issue of the journal examined the safety and efficiency of redeploying a transcatheter aortic valve replacement (TAVR) service during the COVID-19 pandemic [1] . Given the strain on the healthcare system and restriction of services during this contemporary and unprecedented crisis, the authors undertook a pilot study to evaluate the feasibility of a TAVR service streamlined in less than a week to address urgent and emergent cases of severe and symptomatic aortic stenosis. An experienced team was, therefore, moved from a tertiary surgical center with a high COVID-19 admission burden to a hospital with no previous experience in percutaneous valve intervention nor an intensive care unit (ICU) or on-site cardiac surgery.

The main conclusion of the study was that restructuring a TAVR service was possible and effective. It resulted in a reduced time on the waiting list from TAVR clinic visit to procedure as compared to waiting time in the surgical center during the pre-pandemic era (26 vs. 77 days, P < 0.001). Length of in-hospital stay was also significantly reduced from 3 to 2 days. Last but not least, patient outcomes at 30 days in the pre-pandemic era and during the crisis were comparable. Similar rates of combined death and disabling strokes were found, but an increased number of strokes was recorded in the subgroup of patients whose intervention took place in the local private hospital.

First, the authors need to be congratulated for this original study. Acute management of critical patients needing rapid access to TAVR in the context of a global humanitarian crisis is of paramount importance. Efficiency metrics of the TAVR pathway were all significantly improved in the COVID-19 era compared to pre-pandemic, including number of pre-hospitalization visits, time from TAVR clinic to procedure, and length of admission.

Notwithstanding the potential feasibility of minimalist TAVR, it is important to mention that some data need further examination. In fact, on-site cardiac surgery (CS) remains a valuable and unavoidable need in institutions performing TAVR, following major cardiac societies' recommendations [2, 3] . Other study cohorts already examined potential TAVR service without on-site CS and showed promising results [4] . For instance, The AQUA registry proved that among patients undergoing TAVR at hospitals with and without on-site CS, strokes (2.3% vs. 2.6% respectively, P = 0.452), vascular complications (8.9% vs. 10.1% respectively, P = 0.161) and in-hospital mortality (4.2% vs. 3.8% respectively, P = 0.396) were not statistically different [4] . Conversion to sternotomy occurred in 0.3% of cases on the non-surgical sites [4] .

Second, patient selection is critical. Patients admitted for TAVR during the COVID-19 era in this study were deemed at very low surgical risk, which is reflected by their younger age and the lower Euroscore II (3.1 IQR [1.8, 5.4] vs. 4.6 IQR [3.0, 9.0] respectively, P = 0.01). A heart team approval was also integrated in the decisional approach to proceed with the intervention. According to the authors, no compromise to patients' safety was found with the new model of TAVR excluding an on-site surgery service or ICU. However, the study was not powered to evaluate safety outcomes and therefore, could only serve as a hypothesis-generating work.

Surprisingly, a higher number of in-hospital strokes (6% vs 0%) and major vascular complications (6% vs 2%) were found after relocating the TAVR service during the COVID-19 era, despite a younger study group age. These findings remain unexplainable and need to be reassessed carefully to evaluate whether they are attributable to random chance or rather a true procedure-related issue. We could first argue that in the setting of this study, the initiation of a TAVR service in the new center was completed by experienced healthcare professionals. This stance notwithstanding, the need for an ICU team for close monitoring and a multidisciplinary approach remains important to diagnose and treat TAVR-related complications in a timely fashion when needed. These aspects should be explicitly discussed by the heart team beforehand and will allow planning for a bailout valve surgery in the case of TAVR failure.

On the other hand, pacemaker implantation was numerically reduced in the COVID-19 era (10% vs 23%, P = 0.09). As hypothesized by the authors, it is potentially due to an increased use of the balloon-expandable prosthesis Sapien 3 (Edwards Lifesciences, Irvine, CA, USA), which is associated with a reduction in the risk of atrioventricular conduction abnormalities relative to other prostheses [5] . The most important benefit of this practice change was the shorter hospital stay as shown in the study, which was beneficial in the setting of a limited access to resources during the pandemic. Besides its effect on reducing potential conduction abnormalities, this prosthesis may offer other attractive benefits for younger patients in the long term, mainly an easy coronary access if required.

The authors have done a great job trying to extrapolate the potential applicability of this new way of restructuring a TAVR service that could be deployed beyond the COVID-19 era. Patients' pathway from referral was streamlined using telehealth clinics, adequate patient selection to mitigate the surgical risk, and a minimalist approach. The cost-effectiveness of rethinking the organization of this service beyond conventional infrastructures showed promising results. It could potentially be reproduced in the future, with the growing waiting list in TAVR clinics, but also considering risks and expenses related to prolonged hospital stay. The remaining question is whether the absence of an on-site surgery team and ICU could end up being more detrimental. In our continuous effort to make our practice affordable, it must not be forgotten that the well-being of the patient should remain our foremost concern. Whether this new approach proposed by the authors could have long-term sustainability remains undoubtedly a matter of debate until more robust data are available.

None.

There are no conflicts of interest to disclose.

Safety and operational efficiency of restructuring and redeploying a transcatheter aortic valve replacement service during the COVID-19 pandemic: the Oxford experience

Canadian cardiovascular society position statement for transcatheter aortic valve implantation

ESC/EACTS Guidelines for the management of valvular heart disease

Outcomes of transfemoral transcatheter aortic valve implantation at hospitals with and without on-site cardiac surgery department: insights from the prospective German aortic valve replacement quality assurance registry (AQUA) in 17 919 patients

Changes in the pacemaker rate after transition from Edwards SAPIEN XT to SAPIEN 3 transcatheter aortic valve implantation: the critical role of valve implantation height